Boehringer Ingelheim reveals FDA approval of Micardis

Boehringer Ingelheim has revealed that its treatment for patients at high risk of cardiovascular (CV) incidents – Micardis (telmisartan), has been approved by the Food and Drug Administration (FDA).

It is designed for the reduction of the risk of myocardial infarction, stroke or death from CV causes in patients 55 years of age or older.

The drug is the only treatment of its type approved by the FDA for patients at high CV risk who are unable to take ACE inhibitors.

“Now, these patients can be confident that with Micardis, they have a proven, effective and well tolerated option to reduce their risk of severe CV events,” explained Professor Klaus Dugi, corporate vice-president of medical affairs at Boehringer Ingelheim.

This is not the first drug Boehringer Ingeheim has received approval from the FDA for this week.

It also announced that its blood pressure reduction treatment Twynsta (telmisartan plus amlodipine) has been granted authorisation.